P=N/A, N=90, Recruiting, Centre Hospitalier Princesse Grace

P3, N=18, Completed, University of Texas Southwestern Medical Center | Active, not recruiting --> Completed | Trial completion date: Jun 2027 --> Oct 2025

P2, N=100, Not yet recruiting, Peking University People's Hospital

P1/2, N=20, Completed, Universitaetsklinikum Erlangen AR | Active, not recruiting --> Completed

This human 3D multicellular in vitro spheroid model of synovial inflammation recapitulates key RA pathological processes and provides a robust platform for mechanistic studies and therapeutic evaluation.

Persistent DP was associated with higher TJC, greater number of previous b/tsDMARDs, and lower inflammation. No MOA was clearly superior; however, baricitinib may confer a relative benefit within the JAKi class.

Importantly, co-administration of ruxolitinib, a clinically approved JAK1/2 inhibitor, dampened IFN-β signaling and rescued mice from lethal toxicity. Collectively, these findings define the pathophysiological consequences of sustained systemic IFN-β exposure and identify ruxolitinib as a potential mitigation strategy to manage IFN-β-mediated toxicity during OV treatment.

P=N/A, N=20, Completed, Benha University

P3, N=140, Recruiting, University Hospital, Brest | Not yet recruiting --> Recruiting

P3, N=33, Not yet recruiting, University Hospital, Rouen | Trial completion date: Aug 2029 --> Dec 2029 | Trial primary completion date: Aug 2029 --> Dec 2029

P2, N=156, Completed, Minghui Pharmaceutical (Hangzhou) Ltd | Active, not recruiting --> Completed

P1/2, N=13, Terminated, Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Completed --> Terminated; This study was closed due to business reasons. Closure was not prompted by any safety or efficacy concerns.